Characterization of the Cognitive and Motor Changes Revealed by the Elevated Plus Maze in an Experimental Rat Model of Radiation-Induced Brain Injury.
Anxiety
acute radiation syndrome
cognitive dysfunction
depression
elevated plus maze
gamma rays
rats
Journal
Advanced biomedical research
ISSN: 2277-9175
Titre abrégé: Adv Biomed Res
Pays: India
ID NLM: 101586897
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
03
2020
revised:
25
04
2020
accepted:
10
05
2020
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
6
4
2021
Statut:
epublish
Résumé
Experimental models are needed to better understand the pathophysiology of neurodegenerative diseases to develop novel therapeutics. The neuropathology and clinical signs of acute radiation syndrome resemble those of neurodegenerative conditions. We characterized elevated plus maze (EPM) indicators of cognitive and motor impairment in rats exposed to brain-damaging doses of gamma radiation to develop a model for neurological component of the acute radiation syndrome. Technetium 99 m was administered once through tail vein to male Wistar rats to reach an absorbed dose of Gamma radiation of 667 mGy (66.7Rad). Animal performance in the EPM was assessed every 14 days. Rats were observed for 9 weeks for the occurrence of systemic and neurological signs. Comparisons were done between irradiated and nonirradiated rats, and in each group with baseline performance. EPM indicators of cognitive and motor impairment, anxiety, and depression were observed concomitantly and increased with the severity of acute radiation syndrome-like systemic and neurological signs. Alterations in EPM indicators appeared 3 weeks postirradiation and their severity increased with time. Notably, arm transitions and the distance covered in the maze were decreased (-56.71% and -73.62%, Our results suggest that irradiated rat performance in the EPM paradigm reflects disease severity and could be used to perform both acute and subchronic pharmacological studies in acute radiation syndrome-like diseases in rats.
Sections du résumé
BACKGROUND
BACKGROUND
Experimental models are needed to better understand the pathophysiology of neurodegenerative diseases to develop novel therapeutics. The neuropathology and clinical signs of acute radiation syndrome resemble those of neurodegenerative conditions. We characterized elevated plus maze (EPM) indicators of cognitive and motor impairment in rats exposed to brain-damaging doses of gamma radiation to develop a model for neurological component of the acute radiation syndrome.
MATERIALS AND METHODS
METHODS
Technetium 99 m was administered once through tail vein to male Wistar rats to reach an absorbed dose of Gamma radiation of 667 mGy (66.7Rad). Animal performance in the EPM was assessed every 14 days. Rats were observed for 9 weeks for the occurrence of systemic and neurological signs. Comparisons were done between irradiated and nonirradiated rats, and in each group with baseline performance.
RESULTS
RESULTS
EPM indicators of cognitive and motor impairment, anxiety, and depression were observed concomitantly and increased with the severity of acute radiation syndrome-like systemic and neurological signs. Alterations in EPM indicators appeared 3 weeks postirradiation and their severity increased with time. Notably, arm transitions and the distance covered in the maze were decreased (-56.71% and -73.62%,
CONCLUSIONS
CONCLUSIONS
Our results suggest that irradiated rat performance in the EPM paradigm reflects disease severity and could be used to perform both acute and subchronic pharmacological studies in acute radiation syndrome-like diseases in rats.
Identifiants
pubmed: 33816391
doi: 10.4103/abr.abr_62_20
pii: ABR-9-72
pmc: PMC8012866
doi:
Types de publication
Journal Article
Langues
eng
Pagination
72Informations de copyright
Copyright: © 2020 Advanced Biomedical Research.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
J Microsc Ultrastruct. 2017 Oct-Dec;5(4):206-215
pubmed: 30023256
Alzheimers Dement. 2019 Jul;15(7):961-984
pubmed: 31327392
J Neurooncol. 2008 Dec;90(3):357-62
pubmed: 18716713
Radiother Oncol. 2004 Jul;72(1):1-13
pubmed: 15236869
Neuro Oncol. 2010 Feb;12(2):145-52
pubmed: 20150381
Curr Top Med Chem. 2018;18(19):1656-1676
pubmed: 30430939
Neurobiol Dis. 2020 Jan;133:104431
pubmed: 30905768
Neurotoxicology. 2019 May;72:38-50
pubmed: 30738807
Int J Vet Sci Med. 2017 Nov 07;5(2):98-104
pubmed: 30255057
J Headache Pain. 2019 Jan 31;20(1):11
pubmed: 30704400
BMJ. 1988 Sep 24;297(6651):757-70
pubmed: 3142540
Semin Neurol. 2004 Dec;24(4):405-17
pubmed: 15637652
Neurologia. 2003 Sep;18(7):389
pubmed: 14505247
Am J Epidemiol. 1987 Feb;125(2):231-50
pubmed: 3812431
Arch Physiol Biochem. 2018 May;124(2):185-193
pubmed: 28906145
Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):
pubmed: 28716886
Physiol Behav. 2017 Oct 1;179:487-493
pubmed: 28735062
Behav Brain Funct. 2018 Jul 16;14(1):14
pubmed: 30012162
Brain Res. 1976 Oct 29;116(1):49-67
pubmed: 987833
Biomed Pharmacother. 2018 Sep;105:1006-1014
pubmed: 30021335
Neuro Oncol. 2014 Apr;16(4):528-39
pubmed: 24305723
Biochim Biophys Acta. 2016 May;1862(5):915-25
pubmed: 26806700
Med Radiol (Mosk). 1982 Jul;(7):53-8
pubmed: 6289036